Louisiana's lawsuit targeting the FDA's abortion pill policy has landed the Trump administration in a political squeeze before November's midterms. Mifepristone, used in nearly two-thirds of U.S. abortions, remains available via telemedicine and mail after the Supreme Court twice paused a lower court ruling that would have blocked that access. President Trump has stayed silent on the case despite calling himself “the most pro-life president in history.”

The Justice Department declined to submit a brief defending the FDA, a rare move that has drawn criticism from both sides. The administration's silence leaves the legal question unresolved and has angered anti-abortion leaders like Tony Perkins, who accuses Trump of slow-walking a promised safety study that hasn't even begun. Democrats and reproductive rights groups are rallying voters, calling the case proof that midterms matter.

For pharmaceutical companies shipping mifepristone, the uncertainty around FDA policy and congressional oversight remains a regulatory risk. The case has become a rallying point that energizes both sides heading into November, leaving the Trump campaign in a no-win position where any public stance risks either suppressing Republican turnout or galvanizing Democratic voters.